Niraparib
Metastatic Prostate Small Cell Carcinoma
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Metastatic Prostate Small Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin M.D. Anderson Cancer Center | Phase 2 | BB |
Pembrolizumab Rahul Aggarwal | Phase 2 | B |
PREDNISONE TABLETS Fred Hutchinson Cancer Center | Phase 2 | B |
CABAZITAXEL M.D. Anderson Cancer Center | Phase 2 | B |
Alisertib Weill Medical College of Cornell University | Phase 2 | B |
View all 22 →
Same molecule, other indications
Niraparib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →